Literature DB >> 29610118

Behçet's Disease: Pulmonary Aneurysm Resolution with Oral Therapy and HLA B72 Allele Association.

Clarissa de Albuquerque Botura1, Luiz Eduardo Bersani-Amado1, Antônio Rubens Zacarias-Júnior2, Sueli Donizete Boreli3, Naiene Gomes Gordo Stecca4, Bruno Ambrósio da Rocha5, Roberto Kenji Nakamura Cuman5, Ciomar Aparecida Bersani-Amado6.   

Abstract

We report the case of a woman who was diagnosed with a pulmonary artery aneurysm that was caused by Behçet's disease. The patient was initially diagnosed with community-acquired pneumonia and then pulmonary thromboembolism and aneurysm of the right pulmonary artery segmental branch was confirmed. The initial treatment consisted of anticoagulant drugs. After analysis of the family history and a positive pathergy test, the patient was diagnosed with Behçet's disease. Oral pharmacological treatment began with corticosteroids, cyclophosphamide, and anticoagulant suspension. The HLA B72 allele was identified in the patient and her two sisters, demonstrating the familial characteristic of the disease and the presence of this allele in a female patient with Behçet's disease. After 12 months of treatment, the clinical condition completely resolved.
© 2018 Marshfield Clinic.

Entities:  

Keywords:  Behçet’s disease; HLA B72; Pulmonary artery aneurysm

Mesh:

Substances:

Year:  2018        PMID: 29610118      PMCID: PMC6108514          DOI: 10.3121/cmr.2017.1386

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  26 in total

Review 1.  Pulmonary manifestations of Behçet's disease.

Authors:  F Erkan; A Gül; E Tasali
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

2.  Pulmonary artery aneurysms in Behçet syndrome.

Authors:  Vedat Hamuryudan; Tarik Er; Emire Seyahi; Canan Akman; Hasan Tüzün; Izzet Fresko; Sebahattin Yurdakul; Füruzan Numan; Hasan Yazici
Journal:  Am J Med       Date:  2004-12-01       Impact factor: 4.965

3.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 4.  Behcet's disease: epidemiology, clinical manifestations, and diagnosis.

Authors:  Fereydoun Davatchi; Cheyda Chams-Davatchi; Hormoz Shams; Farhad Shahram; Abdolhadi Nadji; Massoomeh Akhlaghi; Tahreh Faezi; Zahra Ghodsi; Bahar Sadeghi Abdollahi; Farimah Ashofteh; Negin Mohtasham; Hoda Kavosi; Mariam Masoumi
Journal:  Expert Rev Clin Immunol       Date:  2016-07-11       Impact factor: 4.473

Review 5.  One year in review 2016: Behçet's syndrome.

Authors:  Gulen Hatemi; Emire Seyahi; Izzet Fresko; Rosaria Talarico; Vedat Hamuryudan
Journal:  Clin Exp Rheumatol       Date:  2016-10-13       Impact factor: 4.473

6.  Close association of HLA-Bw51 with Behçet's disease.

Authors:  S Ohno; M Ohguchi; S Hirose; H Matsuda; A Wakisaka; M Aizawa
Journal:  Arch Ophthalmol       Date:  1982-09

Review 7.  [Cardiovascular involvement in Behçet's disease].

Authors:  A-C Desbois; B Wechsler; P Cluzel; G Helft; D Boutin; J-C Piette; P Cacoub; D Saadoun
Journal:  Rev Med Interne       Date:  2014-01-13       Impact factor: 0.728

Review 8.  Behcet's Syndrome.

Authors:  Sam R Dalvi; Resit Yildirim; Yusuf Yazici
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

9.  Adult Behcet's disease in Iran: analysis of 6075 patients.

Authors:  Fereydoun Davatchi; Cheyda Chams-Davatchi; Hormoz Shams; Abdolhadi Nadji; Tahereh Faezi; Massoomeh Akhlaghi; Bahar Sadeghi Abdollahi; Farimah Ashofteh; Zahra Ghodsi; Negin Mohtasham; Farhad Shahram
Journal:  Int J Rheum Dis       Date:  2015-08-10       Impact factor: 2.454

10.  Faraway from the silk route: demographic and clinical features of Behçet's disease in 106 Brazilian patients.

Authors:  Fabricio Souza Neves; Cezar Augusto Muniz Caldas; Laís Verderame Lage; Cláudia Goldenstein-Schainberg; Célio Roberto Gonçalves
Journal:  Clin Rheumatol       Date:  2009-01-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.